Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 4/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209614 | 0.96 | MEN1 (0.47) | MEN1KMT2APLA2G2APLA2G10KDM4C | |
| SCHEMBL22633364 | 0.92 | KDM4C (0.41) | MEN1KMT2APLA2G2APLA2G10KDM4C | |
| SCHEMBL22653145 | 0.92 | KDM4C (0.41) | MEN1KMT2APLA2G2APLA2G10KDM4C | |
| SCHEMBL3506600 | 0.92 | KDM4C (0.42) | MEN1KMT2APLA2G2APLA2G10KDM4C | |
| SCHEMBL6558221 | 0.85 | MEN1 (0.48) | MEN1KMT2AKDM4CTLR2L3MBTL1 | |
| SCHEMBL19750677 | 0.85 | KDM4C (0.37) | MEN1KMT2AKDM4CPOLBCA1 | |
| SCHEMBL9359454 | 0.84 | MEN1 (0.39) | MEN1KMT2APLA2G2APLA2G10KDM4C | |
| SCHEMBL9359448 | 0.84 | MEN1 (0.39) | MEN1KMT2APLA2G2APLA2G10KDM4C | |
| SCHEMBL21068591 | 0.84 | MEN1 (0.52) | MEN1KMT2AKDM4CL3MBTL1TDP1 | |
| SCHEMBL22787023 | 0.84 | MEN1 (0.52) | MEN1KMT2AKDM4CL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2023-09-21 | — | — | US | disclosed |
| CN-116194084-A | Cleavable lipid compounds, compositions containing the same and uses thereof | 赛诺菲巴斯德有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4182296-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | Sanofi Pasteur (FR) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022013439-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | SANOFI PASTEUR (FR) | 2022-01-20 | — | — | WO | disclosed |
| US-7321059-B2 | Compounds for use as surfactants | GLAXO GROUP LIMITED (GB) | 2008-01-22 | — | — | US | disclosed |
| EP-1436007-B1 | COMPOUNDS FOR USE AS SURFACTANTS | GLAXO GROUP LTD (GB) | 2005-03-30 | — | — | EP | disclosed |
| US-20050048024-A1 | Compounds for use as surfactants | GLAXO GROUP LIMITED (GB) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293447-A1 | CLEAVABLE LIPIDIC COMPOUNDS, COMPOSITIONS CONTAINING THEREOF, AND USES THEREOF | MTTP, CETP, LNPEP | MEN1 3390/4885KMT2A 645/4885PLA2G2A 688/4885 |
| US-20050048024-A1 | Compounds for use as surfactants | SGMS1, AQP1, F12 | MEN1 113/4885KMT2A 4089/4885PLA2G2A 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.